Companion Diagnostics Market worth $11.57 billion by 2031 | MarketsandMarkets™

DELRAY BEACH, Fla., June 15, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Companion Diagnostics Market is projected to grow from about USD 6.31 billion in 2026 to USD 11.57 billion by 2031, at a CAGR of 12.9%.

Browse 350 market data Tables and 250 Figures spread through 450 Pages and in-depth TOC on "Companion Diagnostics Market - Global Forecast to 2031"

Companion Diagnostics Market Size & Forecast:

• Market Size Available for Years: 2025–2031
• 2026 Market Size: USD 6.31 billion
• 2031 Projected Market Size: USD 11.57 billion
• CAGR (2026–2031): 12.9%

Companion Diagnostics Market Trends & Insights:

• The assays, kits & reagents segment captured 67.3% of the total market in 2025.
• Pharmaceutical & biotechnology companies dominated the companion diagnostics market in 2025.
• North America accounted for the largest share of 44.7% in 2025.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=155571681

The market is driven by the rapid adoption of precision medicine, targeted therapies, and biomarker-based treatment approaches. Companion diagnostics (CDx) are essential for identifying patient populations most likely to benefit from specific therapies, particularly in oncology, autoimmune diseases, and rare genetic disorders. The market encompasses diagnostic assays, next-generation sequencing (NGS), PCR-based testing, immunohistochemistry, in situ hybridization, liquid biopsy technologies, bioinformatics platforms, and associated analytical services. Increasing regulatory emphasis on personalized therapeutics, growing pharma-diagnostic partnerships, and expanding approvals of targeted drugs are accelerating market growth globally.

In 2025, the polymerase chain reaction (PCR) captured a major share in the technology segment.

PCR held a major share in 2025 due to its high sensitivity, faster turnaround time, established regulatory acceptance, and broad use in mutation detection and therapy-related testing. However, next-generation sequencing (NGS) is expected to grow faster over the forecast period, supported by elevated demand for multi-gene testing, comprehensive genomic profiling, and broader precision oncology applications.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=155571681

In 2025, cancer was the leading indication segment in the companion diagnostics market.

Cancer was the largest segment in 2025, as most companion diagnostics are linked to oncology therapies. Rising cancer incidence, increasing approvals of targeted therapies and immunotherapies, and the growing need to identify biomarker-positive patients continue to support this segment's dominance.

North America was the largest market for companion diagnostics in 2025.

North America accounted for the highest share in 2025, driven by advanced adoption of precision medicine, a strong oncology testing infrastructure, favorable regulatory pathways, high healthcare spending, and the presence of leading diagnostic and pharmaceutical companies. Meanwhile, the Asia Pacific is expected to grow faster, driven by expanding oncology care, rising adoption of molecular diagnostics, and increasing healthcare investments.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=155571681

Top Companies in Companion Diagnostics Market:

The Top Companies in Companion Diagnostics Market include F. Hoffmann-La Roche AG (Switzerland), Agilent Technologies, Inc. (US), QIAGEN (Netherlands), Thermo Fisher Scientific Inc. (US), Guardant Health, Inc (US), Danaher (US), Abbott (US), Illumina, Inc. (US), Almac Group (UK), bioMérieux (France), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), ARUP Laboratories (UK), Icon Plc (Ireland), Quest Diagnostics(US), Amoy Diagnostics Co., Ltd (China), Tempus AI, Inc (US), Caris Life Sciences, Inc (US), Arup Laboratories(US), Abnova Corporation (Taiwan), Invivoscribe Technologies (US), Q2 Solutions(US), Pillar Biosciences(US), Creative Biolabs(US), EntroGen, Inc.(US), and Biocartis (Belgium).

Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting

Related Reports:

PCR Technologies Market - Global Forecast to 2030

Cancer Biomarkers Market - Global Forecast to 2032

Companion Animal Diagnostics Market - Global Forecast to 2031

Molecular Diagnostics Market - Global Forecast to 2030

Next-generation Sequencing Market - Global Forecast to 2031

About MarketsandMarkets™ 

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

MarketsandMarkets™ SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/

SOURCE MarketsandMarkets